Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744755 | 1.00 | ADRB2 (0.46) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL19574904 | 1.00 | ADRB2 (0.46) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL19121577 | 1.00 | ADRB2 (0.46) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL21612980 | 0.86 | ADRB2 (0.43) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL22911512 | 0.81 | ADRB2 (0.43) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL9746507 | 0.81 | ADRB2 (0.43) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL9737175 | 0.81 | GABRA1 (0.43) | CYP3A4CYP2D6NFKB1CYP1A2PNMT | |
| SCHEMBL24725717 | 0.80 | ADRB2 (0.46) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL17069234 | 0.80 | TSHR (0.50) | ADRB2ADRB1AOC3CYP3A4CYP2D6 | |
| SCHEMBL12204154 | 0.79 | ADRB2 (0.48) | ADRB2ADRB1AOC3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220017541-A1 | INHIBITORS OF ARGINASE | Praxis Biotech LLC | 2022-01-20 | — | — | US | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3380471-B1 | TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-07 | — | — | US | disclosed |
| US-8420689-B2 | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-07 | — | — | US | disclosed |
| US-7923465-B2 | CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-12 | — | — | US | disclosed |
| US-7923465-B2 | CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-12 | — | — | US | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | ADRB2 2931/4885ADRB1 1875/4885AOC3 3970/4885 |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | CNR1, CNR2, GPR18 | ADRB2 61/4885ADRB1 63/4885AOC3 4180/4885 |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | ADRB2 27/4885ADRB1 23/4885AOC3 2052/4885 |
| US-20220017541-A1 | INHIBITORS OF ARGINASE | ARG1, ARG2, ARGLU1 | ADRB2 2825/4885ADRB1 1665/4885AOC3 238/4885 |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | ADRB2 916/4885ADRB1 348/4885AOC3 1719/4885 |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | ADRB2 17/4885ADRB1 9/4885AOC3 2677/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | ADRB2 3165/4885ADRB1 2785/4885AOC3 3632/4885 |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | ADRB2 4538/4885ADRB1 3455/4885AOC3 1034/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | ADRB2 4538/4885ADRB1 3455/4885AOC3 1034/4885 |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | ADRB2 818/4885ADRB1 983/4885AOC3 3514/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | ADRB2 3165/4885ADRB1 2785/4885AOC3 3632/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | ADRB2 19/4885ADRB1 8/4885AOC3 2287/4885 |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | CNR2, CNR1, OPRL1 | ADRB2 273/4885ADRB1 257/4885AOC3 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.